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Introduction
Osteoporosis is a disease characterised by a reduction in bone density with corresponding changes in bone microarchitecture, leading to increased fracture risk particularly of the hip (Genant et al., 2013) , vertebrae (Michalska et al., 2012) and distal radius (Genant et al., 2010) . In the UK, annually there are more than 50,000 osteoporotic hip fractures which often lead to more serious health consequences or mortality. 10% of these patients fail to survive for one month and 30% do not survive beyond one year (Abrahamsen et al., 2009; Clark et al., 2012) . This human cost is mirrored by a health economic implication in the UK of £2 billion per annum. When global statistics are considered the numbers escalate. For example, in China there are approximately >700,000 osteoporotic hip fractures annually (Kanis et al., 2012) .
Bisphosphonates, which reduce osteoclast-mediated bone resorption, are the principle drug class used to treat osteoporosis. Anabolic osteoporosis drugs induce new bone production through an increase in osteoblast number (Jilka et al., 2009 , Jilka et al., 1999 . These anabolic drugs are based upon parathyroid hormone (PTH 1-84, PTH 1-34, teriparatide, Forsteo/Forteo or Teribone™) (Baron and Hesse, 2012; Neer et al., 2001) . Teriparatide refers to recombinant, as opposed to chemically synthesised, PTH 1-34. Whilst a sustained high serum concentration of PTH suppresses bone formation (Horwitz et al., 2005) , intermittent self-administered injections stimulate bone formation (Neer et al., 2001) . Hence, the regimen of administration is essential for obtaining the therapeutic benefit of PTH. The therapeutic window of PTH 1-34 for the treatment of osteoporosis is currently limited to a 24 month period. Forsteo (US PTH 1-34, Eli Lilly) and Forteo (EU PTH 1-34, Eli Lilly) are currently available as a daily 20 µg subcutaneous (SC) injection. Teribone™ (Japan PTH 1-34, Ashai Kasei) is prescribed as a once weekly 56.5 µg SC injection (Nakamura et al., 2012) . The flank is the recommended SC injection site.
Patient compliance to self-injectable PTH 1-84 and PTH 1-34 can be poor (Black et al., 2013; Yu et al., 2012) , and some studies have shown that only 50% of patients continue administering the drug for 6 months after commencing treatment (Briot et al., 2009; Foster et al., 2011) . The reasons for poor compliance to therapy are numerous, but include a dislike of using needles. 10% of the world's population have a needle phobia (Jenkins, 2014) . Selfinjecting can be associated with needle-stick injuries, bleeding, pain at the injection site, bruising and inflammation. Improved compliance to osteoporotic medicines is associated with lower fracture risk therefore providing a significant patient benefit (Weycker et al., 2007) .
Non-injectable delivery of PTH 1-34 for the treatment of osteoporosis is therefore an important unmet clinical need.
Orally delivered protein and polypeptide-based drugs is an attractive option although it is normally inefficacious, due to enzymatic degradation, acid-induced hydrolysis and low absorption in the gastrointestinal tract (Goldberg and Gomez-Orellana, 2003 (Haemmerle et al., 2012; Henriksen et al., 2013; Sturmer et al., 2013) .
Intranasal delivery offers great potential but is a challenging route for proteins and peptides, largely because of unfavourable bioavailability and often poorly tolerated intranasal membrane absorption (permeation) enhancers (Brayden et al., 2012; Illum, 2012; Illum et al., 2012; Lems and den Heijer, 2013) . Both new delivery devices and intranasal mucosal permeation enhancers are being developed to improve nasal delivery of these large molecules (Djupesland, 2013; Fortuna et al., 2014; Pires et al., 2009) . Together these advances aim to surmount the physiochemical and biological barriers previously preventing successful intranasal spray delivery of biological drugs. Our formulation development strategy focuses upon polyethylene glycol (15)-hydroxystearate (Solutol ® HS15) for intranasal absorption-enhancement. The PTH 1-34 intranasal spray formulation is being developed to achieve the required pharmacokinetic profile, mimicking the pulsatile subcutaneous injections with an initial fast absorption profile, which has been shown to promote new bone formation. 
Tissue culture
Saos-2 human osteoblast-like cells are a well-characterised in vitro model, previously shown to express PTHR1 receptors and elicit a cAMP response when treated with parathyroid hormone (Rodan et al., 1987) . Human osteoblast-like Saos-2 cells were purchased from the European Collection of Cell Cultures (Salisbury, UK). Cells were cultured at 37°C, 5% CO2 in 0.2 µm sterile filtered McCoy's 5A, 10% foetal calf serum (FCS), 5mM -glycerophosphate, 50 µg/ml L-ascorbic acid and media changed every 2-3 days. Experiments were performed within a 5-passage window. Cells were seeded at 210 4 cm -2 in tissue culture plates (Corning, UK) and cultured at a sub-confluent density. Mineralisation was confirmed using alizarin red staining at days 7 and 15. Briefly, cells were washed using PBS pH7.4, fixed in 70% ethanol, rehydrated in water and stained using 0.5% alizarin red solution. Digital images were captured using a Nikon Eclipse TS100 inverted microscope (Nikon Instruments, UK).
In vitro bioactivity of PTH 1-34 formulations
Saos-2 cells were exposed to; (1) Phosphate buffered saline (PBS) pH 7.4 0.5% BSA (basal), (2) ⁰C. The resulting 7.5 % w/v Solutol HS15 was allowed to cool and used to prepare the 1 mg/ml PTH 1-34 Solutol ® HS15 formulation. Similarly, the remaining 1 mg/ml PTH 1-34
formulations were prepared using 0.5% Poloxamer, 0.5% and 1% Chitosan and 0.5%
Hyaluronate solutions. Before exposure to the Soas-2 cell cultures the intranasal delivery formulations underwent a 2 stage 1 in 25,000 dilution; 1/125 in PBS/ 0.5% BSA followed by 1/200 in McCoy's 5A/ 0.5% BSA culture medium (Table 1) . This placed formulations with PTH (1-34) at a suitable concentration (~10 nM) for measuring the cAMP response of Soas-2 cells. This dilution is also representative of the dilution of the drug which occurs between the administration of a nasal spray formulation and exposure to the osteoblast in bone within a preclinical or clinical scenario. This is based upon serum concentrations and Cmax from human teriparatide pharmacokinetic studies (Satterwhite et al., 2010; Sturmer et al., 2013) .
Bioactivity was determined by measuring the secondary messenger cAMP produced as a result of PTH 1-34 binding to the PTH receptor. The Saos-2 cells were FCS-restricted for 16h prior to simulation. Following 30 minutes incubation with 25µM rollipram in culture medium, the Saos-2 cells were stimulated with the PTH 1-34 formulations or controls (1) (2) (3) (4) (5) (6) (7) (8) and incubated for a further 60 minutes at 37°C, 5% CO2, washed three times in PBS pH7.4
and lysed according to manufacturer's instructions. Samples were stored at -20°C until cAMP was quantified using ELISA (R&D Systems, Abingdon, UK). Cell numbers were normalised using PicoGreen® DNA quantification (Molecular Probes®, Invitrogen, Paisley, UK).
Pre-clinical pharmacokinetic studies
Male Sprague-Dawley rats, 250g-350g, were housed separately in the Biomedical Support
Unit facilities at the University of Nottingham for a minimum of 7 days for acclimatisation prior to the start of the experiment. Environmental temperature and relative humidity were maintained at 19±2 °C and 55±10 % respectively. Drinking water and a commercial balanced diet was supplied ad libitum.
The intranasal formulation of 1 mg/ml PTH 1-34, 7.5% w/v Solutol ® HS15, 5% w/v mannitol in acetate buffer (pH4) was administered to rats (100 µg/kg). A second group of rats received an intranasal formulation of 1mg/ml PTH 1-34, 5% w/v mannitol in acetate buffer without 7.5% w/v Solutol ® HS15 absorption enhancer. A third group of rats received a formulation a 1 mg/ml PTH 1-34 dosed subcutaneously to enable the calculation of relative bioavailability (80 µg/kg). Rats were sedated in groups of four with 2% v/v isoflurane vapour which was effective for the duration of the intranasal dosing procedure. 25-3 l of the intranasal formulation was placed approximately 5mm into one nostril using a Gilson The nasal spray PTH 1-34 bioavailability was calculated relative to subcutaneous injection in the rat model. A longitudinal series of blood samples was collected in heparinized tubes from the tail vein for 3h post administration. The total amount of blood removed from each animal was below 7% during the whole of the experiment. Plasma was prepared by centrifugation of whole blood at 13,000g for 10min at room temperature. The plasma was immediately frozen at -20°C prior to analysis for PTH 1-34 on an Acquity UPLC with Quattro premier XE mass spectrometer (Waters, Elstree, UK) (Chambers et al., 2013) .
Statistical analysis
Data were subjected to statistical analysis using Prism 6.05 (GraphPad Inc) and Excel 14.0 (Microsoft). Normality of data was assessed using Kolmogorov-Smirnov and distribution plots. ANOVA was accompanied by the Dunnett's post-hoc test. Throughout the manuscript p<0.05 was considered to be statistically significant. Pharmacokinetic data were processed using WinNonLin 5.3 (Pharsight, Certara, USA).
Results
The fundamental phenotypic characteristic of Soas-2 cells to deposit bone mineral on exposure to β-glycerophosphate and ascorbic acid was confirmed by observing a positive Alizarin red stain ( Figure 1A ). Soas-2 cells proliferated, after an initial lag period of four days post seeding, cell numbers made a rapid linear increase over the subsequent 7 days from 1.610 5 cm -2 to 1.410 6 cm -2 ( Figure 1B) . The pharmacokinetic profile after the administration of PTH 1-34 is defined for the intranasal delivery of the formulation with and without Solutol ® HS15, plus a subcutaneous PTH 1-34 injection without Solutol ® HS15 ( Figure 5 , Table 2 ). Intranasally administered PTH 1-34
without Solutol® HS15 was poorly absorbed as identified by the low AUC value (open circles, AUC=140±66.5 ng/ml/min) compared to the subcutaneously administered PTH 1-34 (squares, AUC=1432±409.7 ng/ml/min) and the intranasally administered PTH 1-34 enhanced with Solutol ® HS15 was absorbed well (closed circles, AUC=1393±226.8 ng/ml/min). The bioavailability of intranasally delivered PTH 1-34 enhanced with Solutol ® HS15 in rats was calculated relative to the subcutaneous dose and found to be 78%. There were no significant differences between the pharmacokinetic parameters of the SC injection and those of intranasally delivered PTH 1-34 enhanced with Solutol® HS15 as shown in Table 2 .
The PTH 1-34 half-life for Solutol ® HS15 enhanced intranasal delivery did not differ from that observed for subcutaneous injection. The peak serum concentration (Cmax) of PTH 1-34 was equivalent in subcutaneous and intranasal enhanced administrations, both being significantly greater than non-enhanced intranasal delivery of PTH 1-34 (p=0.016). The pharmacokinetic data obtained in rats provides evidence that the Solutol ® HS15 formulation of PTH 1-34 have potential for intranasal delivery to humans.
Discussion
In this study the bioactivity of intranasal formulations of PTH 1-34 was demonstrated in vitro, A seminal research publication by the late Gideon Rodan's group regarding the characterisation of Saos-2 cells, established the EC50 of PTH 1-34 to be 2.8 nM using an adenylate cyclase secondary messenger assay. This assay identified the incorporation of tritiated adenine into cAMP, whereas in the present studies a cAMP ELISA based assay was used (Rodan et al., 1987) Together, the data in our in vitro studies suggest that the chemically synthesised PTH 1-34 in the various intranasal spray formulations did not have a detrimental effect on the cAMP signalling pathway in human osteoblast-like Saos-2 cells, indicating that PTH bioactivity was not altered Vilardaga et al., 2002) .
Several alternatives to intranasal delivery of PTH are being investigated for the purpose of improving patient adherence to the administration of biological drugs (Cai et al., 2014) .
Successful oral delivery requires the PTH 1-34 formulation to resist proteolysis induced by the harsh acidic gastric microenvironment. New oral delivery approaches such as PTH 1-34 loaded thiolated chitosan nanoparticles and/or pegylated chitosan nanoparticles as well as PTH 1-34 Solutol HS 15/ labrasol emulsions have shown promise in animal models as an alternative administration to injection (Narayanan et al., 2013 (Narayanan et al., , 2014 but as yet have not been translated to the clinic. However, it should be born in mind when interpreting these results that the gastric pathway in animal models may differ significantly from that of humans.
The intranasal route has proven an established route for delivery of a number of drugs to the general circulation and is an expanding field of research (Illum, 2012; Illum et al., 2012; Riese et al., 2014) . A key determinant of the efficacy of a nasal spray formulation of PTH 1-34 is the pharmacokinetics. To investigate this the rat preclinical model was used and it showed that serum levels of PTH 1-34 were significantly greater when Solutol ® HS15 was included in the nasal delivery formulation. We have previously demonstrated that Solutol ® HS15 (CriticalSorb™) is an essential formulation component for the enhancement of the systemic delivery of human growth hormone via the intranasal route . In those studies, the bioavailability in conscious rats of an insulin Solutol ® HS15 formulation delivered nasally was found to be 100 % relative to a subcutaneous injection for the first two hours. The bioavailability of insulin in from the nasal delivery formulation without Solutol® HS15 was near zero (Lewis et al., 2013) . Interestingly, the bioavailability of hGH in combination with 10% and 7.5% Solutol ® HS15 after nasal administration in rats were found to be 49.9 % and 34.3 % respectively . Solutol ® HS15, a mixture of mono-and diesters of 12-hydroxystearate (macrogol 15-hydroxystearate) functions as a non-ionic surfactant with a hydrophilic-lipophilic balance (HLB) value of 14-16. Due to the amphiphilic nature of its components Solutol ® HS15 forms micelles (CMC ~ 0.005% w/v) in solution with a radius of ~6.5 nm. The size of the micelles is not affected by interaction with peptides/proteins and importantly when co-dissolved with Solutol ® HS15, the peptides/proteins retain their tertiary structure (Shubber et al., 2015) . This indicates that there is no direct interaction between the micellar structures and the drug. Solutol ® HS15
has been found to work mainly by enhancing the transcellular transport of the drug across the mucosal membrane and is non-toxic to the mucosal tissue (Brayden et al., 2012) . The The rational regarding pursuing a formulation containing Solutol ® HS15 was supported by data previously published investigating the effect of repeated dosing of Solutol ® HS15 on the nasal mucosa (Illum, 2012) . However this was only a pilot study in a rat model over a 5 day period. Further data, perhaps in a larger animal model, would be beneficial in assessing if there is any irritation to the nasal mucosa by the absorption enhancer Solutol ® HS15 when dosed repeatedly over an extended period.
Other researchers have employed nasal absorption enhancer systems to improve the nasal delivery of PTH. Zelos Therapeutics showed that N-dodecyl--D-maltoside, an enhancer with a similar absorption enhancing mechanism to that of Solutol ® HS15, was able to improve the nasal absorption of a cyclic PTH 1-31 analogue to 35-40% in non-human primates (Krause D et al., 2009 ). Matsumoto et al performed a clinical nasal dosing study of PTH 1-34 with 90 osteoporotic subjects, mean age 66.5 years, and showed nasal administration of 1000 µg PTH 1-34 (a 50 fold dose increase over the 20µg/daily sub cutaneous injection) increased lumbar bone mineral density by 2.4% in 3 months, but concluded greater bioavailability was needed (Matsumoto et al., 2006) .
Clinical applications of nasal spray formulations of PTH 1-34 could be used in combination with other bone regeneration techniques including implanted biomaterial (Reznikov et al., 2016) . Combining bone fracture surgery with post-operative PTH 1-34 nasal spray prescription could improve outcome in scenarios such as Charcot arthroplasty (Pearson et al., 2011; Tamai et al., 2013) and in difficult to treat ankle union (Campbell et al., 2015) .
Furthermore there is potential to combine intranasal PTH 1-34 with experimental therapeutics such as inhibitors of osteoclast-mediated bone resorption, to develop dual action drug combinations for the treatment of osteoporosis.
Conclusion
Overall our data demonstrate the development of a novel intranasal spray formulation of Alizarin red produces a red complex when exposed to calcium mineral deposits. Image taken after Soas-2 cells were cultured for 7 days within a mineralisation promoting culture media containing the active ingredient 5mM -glycerophosphate. This demonstrated that the cell line at the passage numbers we used had maintained an osteoblastic phenotype; Bar = 100µm. B Soas-2 cell population growth.
There is a lag phase in the proliferation of Soas-2 cells following adhesion to the tissue culture plastic (1-4 days). When cultured in the standard medium McCoy's 5A with 10% foetal calf serum (FCS) (solid circles) cells proliferate rapidly between days 4-11. Soas-2 cultured in mineralization medium (solid squares) containing 5 mM -glycerophosphate did not proliferate (1-11 days) (n=2, mean ± SEM, p<0.05). PTH 1-34 concentration in rat plasma following administration via subcutaneous and intranasal routes. Intranasally administered 100 µg/kg 1 mg/ml PTH 1-34 in 5% w/v mannitol within acetate buffer (pH4) not containing Solutol ® HS15 was poorly absorbed (○).Intranasal delivery of 100 µg/kg of 1 mg/ml PTH 1-34 in 5% w/v mannitol within acetate buffer (pH4) with 7.5% Solutol ® HS15 (•).Subcutaneous injection of 80 µg/kg 1 mg/ml PTH 1-34 without Solutol ® HS15 was used to calculate bioavailability (■). Bioavailability of 78% for the intranasal administration of PTH 1-34 in Solutol ® HS15 containing formulation compared to subcutaneous administration. Calculation was dose corrected (n=4, mean ± SD). Table 1 . Formulation and Soas-2 osteoblast-like cells exposure concentration of drug and excipients. Three controls were included; (1) 0.5% Bovine serum albumin (BSA), (2) 7.5% Solutol™ HS15 which was the concentration in the Solutol™ HS15 containing formulation and (3) 1 mg/ml PTH (1-34) alone. Formulations containing 1 mg/ml PTH (1-34) and absorption enhancers, 7.5% Solutol HS15, 0.5% Poloxamer, and 0.5% and 1% Chitosan, were also prepared (4-8). Dilution of these controls and formulations were made with standard medium McCoy's 5A with 10% foetal calf serum (FCS) in all cases. The concentration of PTH (1-34) and excipients exposed to the Soas-2 cells is listed. Table 2 . Pharmacokinetic parameters of PTH (1-34) administered sub-cutaneously, intranasally with Solutol ® HS15 enhancement and intranasally with no enhancer in rats. The peak serum concentration (Cmax) of PTH 1-34, the time at which peak serum concentration of PTH (1-34) was observed (Tmax), the area under the curve (AUC) and PTH (1-34) half-life were determined. No statistical difference between subcutaneous injection and intranasal administrations using Solutol ® HS15 were observed for all pharmacokinetic parameters (p>0.05). 
